Editorial: Second-Generation Antipsychotics for Bipolar Depression in Youths: The Best Evidence Synthesis Is a Strong Call for Further Evidence

J Am Acad Child Adolesc Psychiatry. 2022 Feb;61(2):128-130. doi: 10.1016/j.jaac.2021.07.004. Epub 2021 Jul 14.

Abstract

Before the network meta-analysis (NMA) by DelBello et al. in this issue of the Journal, no NMA had been published on the pharmacological treatment of bipolar depression in youths. DelBello et al. have filled this gap by conducting the first NMA of second-generation antipsychotics for major depressive episodes in youths with bipolar disorder. The NMA by DelBello et al. is arguably the best available evidence synthesis on the comparative efficacy and safety of second-generation antipsychotics for bipolar depression in youths. However, it should be considered as the first building block that strongly calls for more evidence to support clinical decision making in the management of this serious but overlooked condition.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adolescent
  • Antipsychotic Agents* / adverse effects
  • Bipolar Disorder* / drug therapy
  • Depressive Disorder, Major* / drug therapy
  • Humans
  • Network Meta-Analysis

Substances

  • Antipsychotic Agents